Caleium Pharm:Ph3 CAEL-101-301 AL Amyloidosis
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Caelum BioSciences, Inc
Start Date
June 16, 2021
End Date
June 30, 2026
Administered By
Duke Cancer Institute
Awarded By
Caelum BioSciences, Inc
Start Date
June 16, 2021
End Date
June 30, 2026